1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Canada Plasma Fractionation Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Canada Plasma Fractionation Market Revenue and Volume, by Product
8.1.1 Albumin
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Immunoglobulin
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Coagulation Factors
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Protease Inhibitors
8.1.4.1. Market Revenue and Volume Forecast
8.1.5. Others
8.1.5.1. Market Revenue and Volume Forecast
9.1. Canada Plasma Fractionation Market Revenue and Volume, by Application
9.1.1. Immunology & Neurology
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Hematology
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Critical Care
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. Pulmonology
9.1.4.1. Market Revenue and Volume Forecast
9.1.5. Others
9.1.5.1. Market Revenue and Volume Forecast
10.1. Canada Plasma Fractionation Market Revenue and Volume, by End User
10.1.1. Hospitals & Clinics
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Clinical Research Laboratories
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Others
10.1.3.1. Market Revenue and Volume Forecast
11.1. Canada
11.1.1. Market Revenue and Volume Forecast, by Product
11.1.2. Market Revenue and Volume Forecast, by Application
11.1.3. Market Revenue and Volume Forecast, by End User
12.1. CSL Behring LLC.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Octapharma AG
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Grifols S.A.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Takeda Pharmaceutical Company Limited
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Kedrion Biopharma
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. LFB Group
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Biotest AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Bio Products Laboratory
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Green Cross Corporation (GC Biopharma)
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Hema‑Québec (plasma collection and fractionation)
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
